The sofosbuvir-ledipasvir and sofosbuvir-ribavirin combinations are both known to show promising results in the treatment of the hepatitis C virus (HCV) in patients with severe renal impairment. This study aims to determine the effectiveness of the two combinations in the treatment of the hepatitis C virus.
This is an open-label, multicenter, non-randomized study that included a total of 32 patients. All the participants had genotype 1 or 3 HCV infection with a creatinine clearance of less than or equal to 30 mL/min. The participants were divided into two groups; one received the determined dose of sofosbuvir plus ribavirin, and the other received sofosbuvir plus ledipasvir.
The researchers found that patients in the ledipasvir plus sofosbuvir group showed better results than the sofosbuvir plus ribavirin combination. Commonly reported adverse effects were headache, anemia, and fatigue, none of which were related to the treatment. There were no treatment-related cardiac events or other clinically significant changes.
The research concluded that the ledipasvir plus sofosbuvir treatment was safe and more effective in patients with HCV infection and chronic kidney disease when compared to sofosbuvir plus ribavirin treatment.